多西紫杉醇联合卡铂治疗晚期非小细胞肺癌疗效观察

多西紫杉醇联合卡铂治疗晚期非小细胞肺癌疗效观察

郑全理;李书红

【期刊名称】《中国继续医学教育》 【年(卷),期】2016(008)011

【摘要】Objective To observe the curative effect of docetaxel and carboplatin in non-small cell lung cancer (NSCLC).Methods Chose 32 cases of patients who menstrual pathological diagnosis of NSCLC from June 2011 and May 2015, application of docetaxel 40 mg/m2, d 1, d 8, carboplatin 300 mg/m2, d 1, 4 weeks for a cycle, treatment 2~4 cycles, observation of adverse drug reactions.ResultsComplete remission (CR) in 0/32 cases, partial response (PR) in 15/32 cases, stability (SD)in 11/32 cases, progress (PD)in 6/32 cases, total effective rate was 46.9%. Incidence of bone marrow suppression was 100%, 71.8% incidence of gastrointestinal tract reaction was 71.8%.Conclusion Docetaxel and carboplatin in the treatment of NSCLC has good curative effect.%目的：观察多西紫杉醇联合卡铂治疗晚期非小细胞肺癌（NSCLC）疗效。方法选择2011年6月～2015年5月经病理确诊的NSCLC患者32例，应用多西紫杉醇40 mg/m2，d 1、d 8，卡铂300 mg/m2，d 1，4周为1周期，治疗2～4周期，观察药物不良反应。每同期治疗前后评估KPS评分。结果完全缓解（CR）0/32例，部分缓解（PR）15/32例，稳定（SD）11/32例，进展（PD）6/32例，总有效率46.9%。骨髓抑制发生率100%，胃肠道反应发生率71.8%。结论多西紫杉醇联合卡铂治疗NSCLC有较好疗效。